In a report released today, David Saxon from Needham reiterated a Buy rating on NuVasive, with a price target of $80.00. The company’s shares closed last Wednesday at $70.16, close to its 52-week high of $72.61.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of 34.5% and a 83.3% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Globus Medical, and SI-Bone.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NuVasive with a $76.38 average price target, representing an 8.3% upside. In a report issued on April 23, Cowen & Co. also maintained a Buy rating on the stock with a $90.00 price target.
Needham analyst Michael Matson reiterated a Buy rating on Personalis today and set a price target of $33.00. The company’s shares closed last Wednesday at $21.04.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 16.8% and a 69.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
Currently, the analyst consensus on Personalis is a Strong Buy with an average price target of $38.50, a 76.2% upside from current levels. In a report released yesterday, Oppenheimer also upgraded the stock to Buy with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.